---
pmid: '29415125'
title: Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.
authors:
- Bento-Abreu A
- Jager G
- Swinnen B
- Rué L
- Hendrickx S
- Jones A
- Staats KA
- Taes I
- Eykens C
- Nonneman A
- Nuyts R
- Timmers M
- Silva L
- Chariot A
- Nguyen L
- Ravits J
- Lemmens R
- Cabooter D
- Van Den Bosch L
- Van Damme P
- Al-Chalabi A
- Bystrom A
- Robberecht W
journal: Hum Mol Genet
year: '2018'
full_text_available: false
pmcid: PMC6159532
doi: 10.1093/hmg/ddy043
---

# Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.
**Authors:** Bento-Abreu A, Jager G, Swinnen B, Rué L, Hendrickx S, Jones A, Staats KA, Taes I, Eykens C, Nonneman A, Nuyts R, Timmers M, Silva L, Chariot A, Nguyen L, Ravits J, Lemmens R, Cabooter D, Van Den Bosch L, Van Damme P, Al-Chalabi A, Bystrom A, Robberecht W
**Journal:** Hum Mol Genet (2018)
**DOI:** [10.1093/hmg/ddy043](https://doi.org/10.1093/hmg/ddy043)
**PMC:** [PMC6159532](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159532/)

## Abstract

1. Hum Mol Genet. 2018 Apr 1;27(7):1276-1289. doi: 10.1093/hmg/ddy043.

Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.

Bento-Abreu A(1)(2), Jager G(3), Swinnen B(1)(2)(4), Rué L(1)(2), Hendrickx 
S(5), Jones A(6), Staats KA(1)(2), Taes I(1)(2), Eykens C(1)(2), Nonneman 
A(1)(2), Nuyts R(1)(2), Timmers M(1)(2), Silva L(1)(2), Chariot A(7), Nguyen 
L(8), Ravits J(9), Lemmens R(1)(2)(4), Cabooter D(5), Van Den Bosch L(1)(2), Van 
Damme P(1)(2)(4), Al-Chalabi A(6), Bystrom A(3), Robberecht W(1)(4).

Author information:
(1)Department of Neurosciences, Experimental Neurology and Leuven Institute for 
Neuroscience and Disease (LIND), KU Leuven-University of Leuven, B-3000 Leuven, 
Belgium.
(2)Laboratory of Neurobiology, VIB-Center for Brain & Disease Research, B-3000 
Leuven, Belgium.
(3)Department of Molecular Biology, Umeå University, Umeå 901 87, Sweden.
(4)Department of Neurology, University Hospitals Leuven, B-3000 Leuven, Belgium.
(5)Department of Pharmaceutical & Pharmacological Sciences, Pharmaceutical 
Analysis, B-3000 Leuven, Belgium.
(6)Department of Clinical Neuroscience, Institute of Psychiatry, King's College 
London, London SE5 8AF, UK.
(7)GIGA-Molecular Biology of Diseases and Walloon Excellence in Life Sciences 
and Biotechnology (WELBIO), C.H.U. Sart Tilman, B-4000 Liège, Belgium.
(8)GIGA-Neurosciences, University of Liège, C.H.U. Sart Tilman, B-4000 Liège, 
Belgium.
(9)Department of Neurosciences, ALS Translational Research, University of 
California, San Diego, La Jolla, CA, USA.

Amyotrophic lateral sclerosis (ALS) is a fatal degenerative motor neuron 
disorder of which the progression is influenced by several disease-modifying 
factors. Here, we investigated ELP3, a subunit of the elongator complex that 
modifies tRNA wobble uridines, as one of such ALS disease modifiers. ELP3 
attenuated the axonopathy of a mutant SOD1, as well as of a mutant C9orf72 ALS 
zebrafish model. Furthermore, the expression of ELP3 in the SOD1G93A mouse 
extended the survival and attenuated the denervation in this model. Depletion of 
ELP3 in vitro reduced the modified tRNA wobble uridine mcm5s2U and increased 
abundance of insoluble mutant SOD1, which was reverted by exogenous ELP3 
expression. Interestingly, the expression of ELP3 in the motor cortex of ALS 
patients was reduced and correlated with mcm5s2U levels. Our results demonstrate 
that ELP3 is a modifier of ALS and suggest a link between tRNA modification and 
neurodegeneration.

DOI: 10.1093/hmg/ddy043
PMCID: PMC6159532
PMID: 29415125 [Indexed for MEDLINE]
